The user facility reported to terumo cardiovascular that prior to cardiopulmonary bypass, during setup, they were unable to inject and withdraw fluid from the port of the recirculation line fro the bottom of the oxygenator.Per facility, it appeared there was also debris in the end of the line nearest to the port.No patient involvement.The product was change out.
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on december 3, 2021.Upon further investigation of the reported event, the following information is new and/or changed: g6 (indication that this is a follow-up report).H2 (follow-up due to additional information and device evaluation).H3 (device evaluated by manufacturer).H6 (identification of evaluation codes 10, 11, 3331, 706, 25).Type of investigation: #1: 11 - testing of device from same lot/batch retained by manufacturer.Type of investigation #2: 3331 - analysis of production records.Type of investigation #3: 4114 - device not returned.Investigation findings: 706 - assembly problem identified.Investigation conclusions: 25 - cause traced to manufacturing.The affected sample was inspected and confirmed to have excessive bonding agent in the arterial pigtail bond.A representative retention sample was reviewed to show no blockage and normal amounts of bonding agent on the arterial pigtail.The cause of this event was a workmanship error when bonding the arterial pigtail into the oxygenator housing.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|